The same mRNA vaccine technology that powered the rapid development of COVID-19 vaccines has been successfully repurposed to create personalized cancer vaccines capable of targeting solid tumors. BioNTech and the National Cancer Institute jointly announced Phase II trial results showing tumor regression in 67% of participants with late-stage melanoma.
Each vaccine is personalized to the patient's specific tumor mutation profile, identified through whole genome sequencing of the tumor biopsy. The mRNA instructs the patient's immune system to produce proteins that match the tumor's unique neoantigens, effectively teaching T-cells to seek and destroy cancer cells while leaving healthy tissue unharmed.
Trial participants who received the personalized mRNA vaccine alongside pembrolizumab — an existing checkpoint inhibitor — showed a 44% improvement in recurrence-free survival compared to pembrolizumab alone. Researchers are now expanding trials to include non-small cell lung cancer, bladder cancer, and triple-negative breast cancer.